Member Info for sweepie2

Push Technology Wins Prestigious Cloud Award at IBSI Global FinTech Innovation Awards

Under the “Cloud Deployment” Category Push Wins “Most Impactful Project” for GRATISBROKER’s Commission-Free Trading Platform Powered by Diffusion Cloud

SILICON VALLEY, CA, December 12, 2020 – Push Technology, the pioneer and leader in realtime, event-data streaming and messaging solutions, today announced that the Diffusion Intelligent Event-Data Platform, has been named the winner of the “Most Impactful Project” in the Cloud Deployment category for the IBSI (International Banking Systems Intelligence) Global FinTech Innovation Awards held on December 11, 2020. The accolade was received for the event-data consumption, enrichment and delivery technical challenges Diffusion Cloud solved for GRATISBROKER, one of the first, free, online German trading platforms. Robin Amlôt, Managing Editor for IBS Intelligence Ltd. said, “In a year that saw tech take off at speed in financial services, driven by the pandemic, Push Technology and its German client RATISBROKER are to be congratulated on taking home the award for Most Impactful Project in the category of Most Innovative Cloud Deployment.

“The Global Fintech Innovation Awards were established by IBS Intelligence to identify the
best of the best in the world and with 220 entries representing projects across 52 countries we have done just that. GRATISBROKER's new trading platform powered by Push Technology’s Diffusion Intelligent Event-Data Platform was a clear winner in its category, being secure, reliable and scalable, simplifying and streamlining trading activities.” The IBSI Innovation Awards seeks to honor vendors and Banks for their excellence in driving impact through banking technology implementations using emerging technologies. The IBIS awards committee recognized the innovation Push Technology has delivered to GRATISBROKER so that it could address the crucial operational challenges in the cloud of reliably consuming, enriching and delivering hundreds of thousands of trading data events securely and in real-time to their customers. The three major challenges Diffusion Cloud addressed for GRATISBROKER are:
? Assuring real-time trading performance,
? Easily scaling to support high-volume trading events,
? Ensuring the deployment of a secure and reliable cloud infrastructure.
For its commission-free trading platform, GRATISBROKER needed to keep operational staff costs to a minimum while offering customers an attractive product with a rich feature set.Further, the team had to assure high quality-of-service, minimize ongoing administrative overhead, and provide a responsive and intuitive frontend.

Philipp Roeben, Co-Founder & CIO, GRATISBROKER, said: “In addition to the simplicity of use for traders, we have architected our platform with Diffusion in the Cloud to seamlessly scale up and down based upon trading demand; and, using the cloud infrastructure in the most cost efficient way results in min

The vast majority of the sells yesterday were in fact buys, a similar result on Monday should sees moving back up but probably the best thing for AS to do is resign, there would be a massive rebound. I would like to see Matthew take over and AS,SP either moved or sacked. This needs proper news and with the company down playing the Ascom contract it shows that they are content to wait for the exits while they draw an ill deserved salary. It has gone on long enough.
Bring on the AGM

Thursday, December 10, 2020
The Internet of Things (IoT) is here and now, and while there are many benefits to gain from IoT, often security can be left as an afterthought.

The Virtual IoT Security Summit will take place on February 23rd and 24th 2021 and focuses on the reality of IoT security, including real customer examples and use cases for Medical Devices, Healthcare, Industrial, Automotive and more.

Does your organization have a defined strategy or even a simple checklist for your IoT security? If you’re unsure, or you answered no, the Virtual IoT Security Summit will give you all the guidance you and your team need.

With six live talks currently scheduled, with speakers from across the IoT ecosystem, there will be sessions to educate and engage business leaders, technical and product managers, and of course security professionals. More details will be revealed over the coming weeks.

Learn more on the Virtual IoT Security Summit website.

FVR Tick
Wyld Tick
InVMA Awaiting tick
DA Awaiting massive tick
TM Far too early to expect tick

A tad under 1m bought in opening 15 minutes, overhang gone?

ASCOM added to the Our Clients page (just another multi-million pound company)

Our Clients
Wyld Networks has established a global network of IoT partners for LPWAN and mesh networks
hTTps://wyldnetworks.com/clients/

Maarleck23 Nov '20 - 07:37 - 228631 of 228632
0.088889 8 0
As per the information supplied over various bb chats and from companies house, can we extrapolate, 1 million shares at a value of £21.505; is there an VC investment coming in that will value INVMA at £21.5 million?

That would give Tern’s holding of INVMA (50%) valuation nearly 10x the current £1 million book value. That would immediately add about 40% to the share price. Obviously less the VC’s percentage of holding.

Tonight’s presentation could be very enlightening.

Somebody else has the same thinking from ADVFN

Maarleck23 Nov '20 - 07:37 - 228631 of 228632
0.088889 8 0
As per the information supplied over various bb chats and from companies house, can we extrapolate, 1 million shares at a value of £21.505; is there an VC investment coming in that will value INVMA at £21.5 million?

That would give Tern’s holding of INVMA (50%) valuation nearly 10x the current £1 million book value. That would immediately add about 40% to the share price. Obviously less the VC’s percentage of holding.

Tonight’s presentation could be very enlightening.

Never know it could well be external funding coming it, as a few weeks ago it was reported that they had a VC pitch. Nice if it was £5m for 20%, not outrageous when you have a solution like assetminder as a product

Rollovers, bid did not move on either trade

If they can do this then what the value ?
and to rehearse their actual patient cases multiple times ahead of ever stepping into the OR. This may sound like science fiction, but will be a reality sooner than you think.”
When asked whether we had anything else to look forward to this was the reply
Always plenty to look forward to but nothing confirmed just yet!

FYI
Awards tomorrow for FVR, good luck to them

Secure 1:1 video consultation system built for healthcare professionals, with patients at its heart.
Get up & running quickly with the Care Connect white label telehealth platform.

A secure and managed App based video consultation system that allows one-way scheduling and calling between healthcare professionals and their patients. Bespoke web-based content management system (CMS) supports the Apps ensuring your organisation controls all access and video calls. GDPR compliant with no identifiable data held within the App to simplify internal sign off.

Bespoke to you, Care Connect can be adapted to your specific needs, brand and content.

Secure Login App Branded
1234
Care Connect App
Support high levels of patient care:

Improve patient satisfaction by offering video consultations at home, work or even on holiday, at a time that is convenient
Provide solutions to queries in minutes, reducing stress and worry
Reduce avoidable patient days off work
Avoid missed appointments, and improve triage to connected care pathways
Reduce travel costs and environmental impact for patients and professionals
Integrates into your existing home & hospital discharge care services

Features :

Easy on-boarding from the Apple and Google Play stores – connect in minutes
Securely encrypted 1:1 video consultations
Only Healthcare Professionals can schedule and initiate calls
‘Flip the screen’ to share patient view of wounds, dressings and equipment to resolve issues in real time.
All app, video consultation access and management entirely in your control
Add content and links to share important information
GDPR compliant
Branded to your organisation and adapted to your specific needs

FVR Management appointment as promised

RENOWNED MEDICAL FUTURIST DR. RAFAEL GROSSMANN JOINS THE FUNDAMENTALVR GLOBAL MEDICAL PANEL
FundamentalVR explores the future of medical education following the surge in adoption of immersive solutions during COVID-19
LONDON – November 11, 2020 – FundamentalVR, global leaders in using immersive technology to improve the way surgeons are trained, announces healthcare futurist, Dr. Rafael Grossmann, has joined its Global Medical Panel. Dr. Grossmann joins an esteemed panel of healthcare leaders and medical professionals to advise the company as it continues to assess the latest advances in immersive technologies and deploy cutting-edge simulations that power a new era of training for medical educators, device manufacturers, and life science companies.

A respected thought leader and pioneering healthcare and education futurist, Dr. Grossmann is dedicated to integrating technology into medical care and driving innovations to improve the overall healthcare system. He is a full-time practicing surgeon in Maine, specializing in general, trauma, advanced laparoscopic, single incision, and robotic-assisted surgeries. In 2013, he was the first doctor ever to use Google Glass during live surgery and is a passionate advocate of technology’s transformative potential to improve patient care. A global speaker at events including TEDx, Exponential Medicine, and MedicineX, Dr. Grossmann often lectures on innovations in healthcare and how the growth in mobile and wearable platforms will improve connectivity, communication, and data management to help make medicine more efficient, intuitive, and less expensive.

“The COVID-19 pandemic has brought challenges, but resulted in huge advancements in the use of immersive technologies. Now a proven solution, we are actively bringing new products to market using virtual reality for medical device and life science companies, providing a scalable sales training platform with objective measurement to enable better skills transfer, remotely, bridging the physical divide at scale,’’ said Richard Vincent, co-founder, and CEO of FundamentalVR. “As a working surgeon and leading advocate for the future of medical technology, we are delighted to welcome Dr. Grossmann to our Global Medical Panel. I’m excited to work with him to explore new ways of helping surgeons, hospitals, and the wider health industry improve patient outcomes.”

FundamentalVR solutions are powered by its patented HapticVRTM technology architecture that mimics the physical cues of surgical actions, medical tools, and tissue variations within immersive, data-driven medical educational simulations. Delivered through its Fundamental Surgery platform, it allows users to experience the same sights, sounds, and feelings they would in a real operating room. Every user interaction from the surgical gaze, respect for tissue, and movement efficiency is measured and recorded to provide a level of analysis not currently avail

ovember 9, 2020

Hot off of the press on raising £1.1M Talking Medicines are building out a world class product and tech team to realise its mission of creating the world’s first social intelligence company for the pharmaceutical industry. In line with plans to scale up its AI-based data technology platform for measuring patient sentiment, the size of the team will double. COO Elizabeth Fairley commented: “We are keen to attract talented NLP data scientists and a world class product team who are working at at the leading edge of their profession, and who want to join us in our fast and ambitious journey to create a product roadmap that will change the way patient intelligence can be accessed by pharmaceutical companies.”

Recruitment has been boosted with the support of Fabrice Retkowsky, the former CTO of social intelligence company Brandwatch. Fabrice has been working with Talking Medicines as a consultant since September & has been instrumental in creating a hiring plan that will attract top global talent. With his experience of developing Brandwatch into a global technology leader he is well placed to advise the team at Talking Medicines.

Talking Medicines have an HQ in Glasgow, and an office base in London. As the company scales globally it is envisaged that the team will be based globally. During Covid-19 the team have all worked remotely and this has been a big success for the Company. New employees will be attracted to the opportunity to make a difference to both patient outcomes along with creating a world class product. Personal growth matters and employees are given plenty of opportunities to learn new technologies, practices and techniques with room to grow. Talking Medicines embrace diversity and equal opportunity and are committed to building a team that represents a variety of backgrounds and perspectives.

Open roles include:
https://talkingmedicines.com/wp-content/uploads/Talking-Medicines-NPL-Expert.pdf

https://talkingmedicines.com/wp-content/uploads/Talking-Medicines-Head-of-Engineering.pdf

https://talkingmedicines.com/wp-content/uploads/Talking-Medicines-Backend-Developer.pdf

https://talkingmedicines.com/wp-content/uploads/Talking-Medicines-Frontend-Developer.pdf

https://talkingmedicines.com/wp-content/uploads/Talking-Medicines-Data-Science-Engineer.pdf

Full details are found on https://talkingmedicines.com/careers/

Tern plc* (TERN.L, 10.25p/£30.9m)
New investment: Investment in Talking Medicines (04.11.20)
£860k investment in digital health data company, Talking Medicines, for a 23.4% holding. Tern was the lead investor in the £1.1m syndicated funding alongside the Scottish Investment Bank, Scottish Enterprise's investment arm, that followed its initial investment.
Talking Medicines, based in Glasgow and London, uses advanced artificial intelligence (AI), machine learning (ML) and natural language processing (NLP) techniques to provide pharmaceutical companies with real time data intelligence. It looks to capture the 'global digital voice' of the patient from numerous unstructured online sources and connected devices and determine trends and patterns of patient sentiment around medicines.
Funds will be used to grow its product team in order to launch its new AI data service and thereby scale its patient database and customer base. For the year ended August 2019, Talking Medicines made an unaudited retained loss of £0.2m and >£1m has been invested in the company to date.
Tern's second IoT healthcare investment and expands its position in the digital health market. Tern now has six portfolio companies. The investment is into non-participating preference shares with a 6% coupon that can be converted at an initial 1:1 rate. Tern is entitled to appoint the Chair of the board and have one board observer.
Allenby Capital comment: A material investment that increases Tern's portfolio to six companies and represents its second investment in the IoT healthcare market and there are potential synergies with other portfolio companies through the use of AI, ML and NLP. Tern's strategy is to take meaningful stakes in investee companies and operates a hands-on management style and encourages collaboration across the portfolio.

Talking Medicines, the world’s first social intelligence company for the pharmaceutical industry, has received a significant boost with a £1.1 million funding deal to scale up its AI-based data technology platform for measuring patient sentiment.

Tern Plc, the investment company specialising in the Internet of Things (“IoT”), is the lead investor in a syndicated funding round of £1,100,000 alongside Scottish Investment Bank, Scottish Enterprise’s investment arm.

Led by CEO Jo Halliday alongside co-founders Dr Elizabeth Fairley and Dr Scott Crae, Talking Medicines will use the funds to support the launch and roll-out of a new AI data platform, which will translate what patients are saying into actionable pharma grade intelligence by providing a global patient confidence score by medicine. As part of these plans, the business intends to immediately recruit 9 new employees to the NLP data tech team.

Formed in 2013 to create new ways of capturing the voice of the patient, Glasgow-based Talking Medicines uses a combination of Artificial Intelligence, Machine Learning and Natural Language Processing tech tools to capture and analyse the conversations and behaviours of patients at home, with the aim of transforming big pharma’s understanding of patient sentiment.

Through mapping the patient voice from social media and connected devices to regulated medicine information, Talking Medicines is able to build data points to determine trends and patterns of patient sentiment across medicines. This intelligence enables pharmaceutical companies to make patient centric marketing decisions, driving more effective medicines and marketing spend.

Real-time, compliant intelligence can replace traditional focus groups, prescriber reports and clinical target patient profiles to tell pharmaceutical companies who is using their medicines, how, and what they really think of their brands.

Talking Medicines has now raised £2.5 million to date, including three previous seed funding rounds with previous investors including impact investor SIS Ventures and the Scottish Investment Bank.

Since launching 7 years ago, the business has scooped a number of accolades for its innovative approach including winning Rising Stars 2.0, a competition to select the rising stars of UK tech. Most recently, the business was chosen to join Tech Nation’s Applied AI 2.0 Growth Programme, designed to champion and support ‘the UK’s most exceptional deep tech scaleups’.

Talking Medicines CEO, Jo Halliday, said: “We are delighted that Tern is joining our investor group, and Al Sisto will be bringing his wealth of experience to the Board. Now more than ever we passionately believe that big pharma needs a systematic way to make data driven decisions through accessing high grade social intelligence driven from the patient. This investment will scale our team and the development of our AI, ML, NLP tech tools to translate what patients are saying into actionable pharma grade intell

Surely a solution that the Olympics would be interested in but far too soon to be at wally's level of confidence but tomorrow the rocket will be back on course.

Cracking news and only the start

Very true but a relationship is there but you are very right a partner is a big step from a client

Price went up because of the amazing Wyld webinar when nothing appeared from Tern traders took their profits and moved on but after Wyld produced their update on the web site and the Tern one code I'm hopeful we will see it tomorrow hopefully with the first of the resellers names and if a biggie expect a good reaction

https://wyldnetworks.com/clients/

Been there for quite awhile